Effects of AGBL2 on cell proliferation and chemotherapy resistance of gastric cancer.

Hepato-gastroenterology Pub Date : 2015-03-01

Haitao Zhu, Zhichao Zheng, Jianjun Zhang, Xiaoping Liu, Yang Liu, Wei Yang, Yong Liu, Tao Zhang, Yan Zhao, Yanqing Liu, Xiaohui Su, Xiaohu Gu

{"title":"Effects of AGBL2 on cell proliferation and chemotherapy resistance of gastric cancer.","authors":"Haitao Zhu, Zhichao Zheng, Jianjun Zhang, Xiaoping Liu, Yang Liu, Wei Yang, Yong Liu, Tao Zhang, Yan Zhao, Yanqing Liu, Xiaohui Su, Xiaohu Gu","doi":"","DOIUrl":null,"url":null,"abstract":"Background/aims: The present study aimed to investigate the expression status of AGBL2 and its inhibitor latexin, and elucidate their clinical implications in gastric cancer.Methodology: AGBL2 expression status was examined in gastric cancer cells and 256 gastric cancer specimens by immunohistochemistry staining. The relationship between AGBL2 protein expression and clinicopathological parameters and prognosis was subsequently determined.Results: AGBL2 expression was determined to be related to pathological tumor and nodal stages by Spearman's regression correlation analysis. The Cox regression test identified AGBL2 protein expression as an independent prognostic factor. AGBL2 and latexin were- found to be related to proliferation and chemotherapy resistance. The 2 proteins also formed immune com- plexes in immunoprecipitation experiments.Conclusions: Our results demonstrate that AGBL2 interacts with latexin, regulating the tubulin tyrosination cycle. It is therefore a potential target for intervention.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"497-502"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aims: The present study aimed to investigate the expression status of AGBL2 and its inhibitor latexin, and elucidate their clinical implications in gastric cancer.

Methodology: AGBL2 expression status was examined in gastric cancer cells and 256 gastric cancer specimens by immunohistochemistry staining. The relationship between AGBL2 protein expression and clinicopathological parameters and prognosis was subsequently determined.

Results: AGBL2 expression was determined to be related to pathological tumor and nodal stages by Spearman's regression correlation analysis. The Cox regression test identified AGBL2 protein expression as an independent prognostic factor. AGBL2 and latexin were- found to be related to proliferation and chemotherapy resistance. The 2 proteins also formed immune com- plexes in immunoprecipitation experiments.

Conclusions: Our results demonstrate that AGBL2 interacts with latexin, regulating the tubulin tyrosination cycle. It is therefore a potential target for intervention.

本刊更多论文

AGBL2对胃癌细胞增殖及化疗耐药的影响。

背景/目的:本研究旨在探讨AGBL2及其抑制剂latexin在胃癌中的表达状况，并阐明其在胃癌中的临床意义。方法:采用免疫组化染色法检测胃癌细胞和256例胃癌标本中AGBL2的表达情况。随后确定AGBL2蛋白表达与临床病理参数及预后的关系。结果:通过Spearman回归相关分析确定AGBL2的表达与病理肿瘤及淋巴结分期有关。Cox回归检验发现AGBL2蛋白表达是一个独立的预后因素。发现AGBL2和latexin与增殖和化疗耐药有关。在免疫沉淀实验中，这两种蛋白也形成免疫复合物。结论:我们的研究结果表明AGBL2与乳胶蛋白相互作用，调节微管蛋白酪氨酸化周期。因此，它是一个潜在的干预目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepato-gastroenterology 医学-外科

自引率

0.00%

发文量

审稿时长

1.9 months

期刊介绍： Hepato-Gastroenterology has been discontinued as of 2015. Extremely limited quantities of back issues in print available for sale.